|Titel||Psychiatric Comorbidity, Psychological Distress and Quality of Life in Gamma-hydroxybutyrate (GHB) Dependent Patients.|
|Jaar van publicatie||2016|
|Auteurs||Kamal RM, Dijkstra BAG, van Oene GH de Weert, van Duren JAM, DeJong CA|
|Uitgave||J Addict Dis|
|Publicatiedatum||2016 Jul 22|
BACKGROUND AND OBJECTIVE: Understanding the psychiatric state and psychological distress level of patients with GHB dependence is important to develop effective detoxification and relapse management methods. Our aim is to assess the prevalence among GHB-dependent individuals of psychiatric comorbidity and psychological distress levels and their association with the individuals' pattern of misuse and quality of life.
METHODS: Ninety-eight patients were tested with the Mini International Neuropsychiatric Interview-plus (MINI-plus), Brief Symptom Inventory (BSI), Depression Anxiety Stress scale (DASS) and EuroQol-5D as a part of the Dutch GHB detoxification monitor in seven addiction treatment centers. Participants were selected from those undergoing inpatient GHB detoxification treatment between March 2011 and September 2012.
RESULTS: Males accounted for 68% of the participants and the average age was 28 years old. A high rate of psychiatric comorbidity (79%) was detected, including anxiety (current 38%, lifetime 40%), mood (13%, 31%), and psychotic disorders (13%, 21%). The level of psychological distress was significantly higher than the standard outpatient reference group, especially in patients with current psychiatric comorbidity (BSI Global Severity Index mean 1.61 versus 1.09, p≤ .01). Increased GHB misuse (higher dose and shorter interval between doses) was associated with the presence of lifetime psychosis, current mood disorders (rpb = .23, p = 0.025) and psychoticism as symptom of psychological distress. Current anxiety, mood disorders and high psychological stress had a negative effect on participants' quality of life.
DISCUSSION: GHB dependence is characterised by serious psychiatric comorbidity and psychological distress, both of which are in turn associated with increased GHB use and a lower quality of life. This needs to be considered during detoxification to avoid complicated withdrawal. Providing treatment for patients' mental health issues is vital for ensuring treatment compliance, avoiding relapse and improving patients' quality of life.
|Alternatieve uitgave||J Addict Dis|